Drug intelligence / Profile preview

let-7f inhibitor

Development stage
Preclinical
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intranasal, Intrathecal, Subcutaneous, Intratumoral, Intralesional, Intraperitoneal, Parenteral
01

Overview

A let-7f inhibitor is a research-grade oligonucleotide designed to bind and neutralize the microRNA let-7f. In the context of systemic lupus erythematosus (SLE), let-7f has been identified as significantly downregulated in bone marrow-derived mesenchymal stem cells (BM-MSCs) compared to healthy controls. Experimental inhibition of let-7f in these cells has been shown to impair BM-MSC proliferation, increase apoptosis, and disrupt the balance between regulatory T (Treg) and T helper 17 (Th17) cells. This effect is mediated through the upregulation of interleukin-6 (IL-6), a direct target of the let-7 family, and the subsequent activation of the STAT3 signaling pathway. While primarily used as a laboratory tool to elucidate disease pathogenesis, the manipulation of let-7f expression in BM-MSCs is considered a potential therapeutic strategy for treating SLE patients.

Other names
anti-let-7fanti-let7fanti-let 7flet-7f antagomirlet7f antagomirlet 7f antagomirlet-7f antisense oligonucleotidelet7f antisense oligonucleotidelet 7f antisense oligonucleotide
02

Targets

let-7 (Lethal-7 microRNA family)let-7f (Lethal-7f microRNA)pre-let-7f (Pre-let-7f microRNA)

Beyond the preview

Go deeper on let-7f inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on let-7f inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call